Clinical Trials Logo

Filter by:
NCT ID: NCT02889302 Completed - Clinical trials for Spinocerebellar Degeneration

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Start date: November 15, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients.

NCT ID: NCT02888210 Completed - Cataract Clinical Trials

A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Start date: September 3, 2016
Phase: Phase 3
Study type: Interventional

To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes

NCT ID: NCT02886728 Completed - Clinical trials for Rheumatoid Arthritis

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

FINCH 3
Start date: August 8, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).

NCT ID: NCT02885662 Completed - Clinical trials for Primary Aldosteronism

Study of CS-3150 in Patients With Primary Aldosteronism

Start date: September 2016
Phase: N/A
Study type: Interventional

To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.

NCT ID: NCT02884726 Completed - Advanced Cancer Clinical Trials

Phase 1 Study of Mesothelin-ADC

Start date: October 14, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in subjects with advanced and/or metastatic solid tumors.

NCT ID: NCT02884635 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

Start date: September 16, 2016
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.

NCT ID: NCT02877134 Completed - Crohn Disease Clinical Trials

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

TRIDENT
Start date: August 25, 2016
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

NCT ID: NCT02875834 Completed - Hyperkalemia Clinical Trials

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

HARMONIZE GL
Start date: March 3, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

NCT ID: NCT02875080 Completed - Healthy Adult Male Clinical Trials

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Start date: September 27, 2016
Phase: Phase 1
Study type: Interventional

The ratios of the geometric means of the ODT formulation to those of the reference formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of brexpiprazole (OPC-34712)).

NCT ID: NCT02873936 Completed - Clinical trials for Rheumatoid Arthritis

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

FINCH 2
Start date: July 27, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.